[144] LKQ Corporation SEC Filing

Rhea-AI Filing Summary

On 30 June 2025 Akari Therapeutics plc (AKTX) filed an 8-K summarizing the voting outcomes of its 2025 Annual General Meeting.

• Equity Incentive Plan: Shareholders increased the 2023 plan pool by 11.026 billion ordinary shares (5.513 million ADSs), raising the total to 19.806 billion shares (9.903 million ADSs). This equates to potential dilution of roughly 17 % relative to the 65.2 billion shares entitled to vote.
• Director Compensation: A one-time grant of options over 1.35 million ADSs (2.7 billion shares, 4.2 % of current capital) to six directors was approved.
• Board & Governance: All seven Class A directors were re-elected. FY-2024 financial statements and the remuneration report received advisory approval. BDO USA, P.C. and HaysMac LLP were confirmed as U.S. and U.K. auditors, respectively.
• Capital Authority: A general authority to allot up to USD 20 million nominal value of new shares and a five-year waiver of pre-emption rights were passed, providing management flexibility for equity financing.

All resolutions passed by wide margins, signalling strong shareholder support. The filing contains no new operating or earnings figures; the principal takeaway is the expanded capacity for equity issuance and compensation grants, which could dilute existing holders if fully utilized.

Positive

• All 15 resolutions passed, reflecting strong shareholder confidence in management and corporate strategy.
• Re-election of directors and auditor confirmations maintain continuity and governance stability.

Negative

• Increase of 11.0 billion ordinary shares for equity incentives represents potential dilution of roughly 17 % of current share count.
• Authority to allot additional shares without pre-emption rights heightens future financing dilution risk for existing shareholders.

Insights

Corporate Governance Specialist

TL;DR – Governance stable; shareholders endorse board and plans, but equity pool enlarged.

Shareholders approved every proposal, including director re-elections, auditor appointments and remuneration items, indicating confidence in the board. The expanded equity incentive pool and new allotment authority align compensation and financing tools with strategic flexibility, yet remain within typical U.K. corporate practice because future issuances still require board action and market disclosure. From a governance perspective, the meeting reinforces continuity and transparency, earning a neutral stance on impact.

Equity Analyst

TL;DR – Potential dilution rises ~17 %; near-term neutral, longer-term pressure possible.

The 11 billion-share increase to the incentive plan plus option grants gives management headroom equivalent to about one-sixth of current outstanding shares. Combined with a USD 20 million allotment mandate and pre-emption waiver, Akari now has ample room to raise equity or fund stock-based compensation. While no shares are issued today, the expanded capacity could weigh on valuation multiples if exercised, particularly for a micro-cap biotech where dilution has historically been a key risk. Absence of fresh clinical or financial catalysts in the filing keeps the immediate market impact muted, but investors should monitor subsequent share issuances closely.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Robert W. Baird & Co. 777 E Wisconsin Avenue Milwaukee WI 53202	5000	183332.20	258147675	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/19/2021	RSU Vesting	Issuer			9511	02/19/2021	RSU Vesting

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Dominick Zarcone C/O LKQ CORPORATION 5846 Crossings Blvd. ANTIOCH TN 37013	Common	06/02/2025	15000	598086.27
Dominick Zarcone C/O LKQ CORPORATION 5846 Crossings Blvd. ANTIOCH TN 37013	Common	05/08/2025	10000	398572.98
Dominick Zarcone C/O LKQ CORPORATION 5846 Crossings Blvd. ANTIOCH TN 37013	Common	05/01/2025	5000	190119.40
Dominick Zarcone C/O LKQ CORPORATION 5846 Crossings Blvd. ANTIOCH TN 37013	Common	04/01/2025	15000	632255.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many additional shares did Akari Therapeutics (AKTX) add to its 2023 Equity Incentive Plan?

11,026,000,000 ordinary shares (5,513,000 ADSs) were added, raising the pool to 19.806 billion shares.

What is the potential dilution from the newly approved equity pool relative to current shares outstanding?

Approximately 17 % of the 65.23 billion ordinary shares entitled to vote at the AGM.

Were all director nominees for Akari Therapeutics re-elected at the 2025 AGM?

Yes. All seven Class A directors received majority support and were re-elected.

Which firms will audit Akari Therapeutics in 2025?

BDO USA, P.C. (U.S. registered) and HaysMac LLP (U.K. statutory) were ratified as auditors.

Did Akari shareholders approve the authority to issue new shares without pre-emption rights?

Yes. A special resolution empowers the board for five years to issue equity for cash without applying pre-emption rights.

What stock option awards for directors were approved at the AGM?

One-time options over 1,350,000 ADSs (2.7 billion shares, 4.2 % of capital) vesting between 2025 and 2027.